Council for europe portal
Language : en Search
Choose language

Newsroom

European network of OMCLs / Human Biologicals (OCABR) / Vaccines | News | 11 December 2018 | Strasbourg, France
In line with the removal of the abnormal toxicity test (ATT) from the European Pharmacopoeia (Supplement 9.6), the 21 product-specific guidelines for Official Control Authority Batch Release (OCABR) of vaccines for human use that contained references to the ATT in the manufacturer’s protocol section (Section 3) have been revised to delete the test.
European network of OMCLs | News | 17 October 2018 | Strasbourg, France
Following the detection of the impurity NDMA (N-nitrosodimethylamine) in valsartan at the end of June, the EDQM has conducted a complete review of the manufacturing information submitted in all Certificate of suitability (CEP) applications for valsartan and other structurally related active substances. The EDQM contacted those manufacturers of valsartan and other sartans holding CEPs which might...
European network of OMCLs | News | 11 October 2018 | Strasbourg, France
Today the first method for simultaneous determination of NDMA and NDEA in Sartan tablets, developed and validated for Valsartan tablets has been released by the German OMCL in Karlsruhe.